Adaptive Biotechnologies Showcases clonoSEQ® Data at ASH, Highlighting Advances in Blood Cancer Care and MRD Assessment

Pfizer Showcases Advancements in Hematology and Breast Cancer at ASH and SABCS 2023

GeNeuro Presents Precision Medicine Approach for ALS at Global Symposium

Prevention and Screening Drive Majority of Cancer Death Reductions Over 45 Years

Alithea Genomics Launches MERCURIUS™ Full-Length DRUG-seq Technology for Large-Scale RNA Sequencing

AstraZeneca’s Imfinzi (Durvalumab) Approved for Limited-Stage Small Cell Lung Cancer in the U.S.

BioLizard Launches Bio|Verse Navigator: Transforming Biomedical Data into Insights

Foresight Diagnostics Launches SHORTEN-ctDNA Trial to Personalize DLBCL Treatment and Reduce Toxicity

Thermo Fisher Scientific Unveils CTS™ Detachable Dynabeads™ CD4 and CD8 for Advanced Cell Therapy

Oncocyte Unveils Breakthrough Liquid Biopsy for Brain Tumor Diagnostics with DetermaCNI™

FDA Approves BIZENGRI® for NRG1+ Pancreatic Cancer and NSCLC

REVEAL GENOMICS and IEO Launch Impact Study on HER2DX® Test to Advance Personalized Treatment in HER2+ Breast Cancer

FDA Grants Breakthrough Therapy Designation to Merck’s Sacituzumab Tirumotecan for EGFR-Mutated NSCLC

Spur Therapeutics Unveils SPR301: A Novel Gene Therapy for GBA1-Linked Parkinson’s Disease

M | O | C Cancer Care & Research Centre Achieves CAR-T Therapy Milestone

Home
/
expert-voices
/
details

Pioneering Advances: Precision Oncology Transforming Cancer Treatment at Fortis Hospitals

NextEdge Admin

27 Feb 2024

3 min 17 sec

Dr Boman Dhabhar

Director Oncology, Fortis Mulund

Dr Niti Raizada, Senior Director – Medical Oncology and Hemato Oncology, Fortis Hospitals, Bengaluru quotes-

“Bangalore is rapidly becoming a frontrunner in precision oncology, a personalized approach to cancer treatment that promises hope for improved outcomes and patient well-being. This paradigm shift moves away from one-size-fits-all therapies and delves into the unique genetic blueprint of each tumor. The rise of precision oncology in Bangalore isn’t confined to high-tech giants. Collaboration is key too – hospitals, research institutions, and tech companies are coming together to create a robust ecosystem for clinical trials and the development of novel therapies. Challenges like infrastructure need to be strengthened, and awareness about precision oncology among both patients and healthcare providers needs to be amplified. Ethical considerations regarding data privacy and equitable access must be addressed. Precision oncology offers a glimmer of hope, not just for individual patients but for the future of cancer care. As Bangalore continues to embrace this revolutionary approach, it paints a picture of a future where cancer battles are fought with personalized precision, offering a brighter horizon for those facing this formidable foe.”

Dr Boman Dhabhar, Director-Medical Oncology, Fortis Hospital Mulund says –

“Precision oncology, also known as personalized or targeted therapy, aims to treat the patient with the right treatment at the right time. It is mainly used for patients who suffer from advanced malignancy and those who have limited options for treatment.

The future of precision oncology holds significant promise as advancements in technology, genomics, and our understanding of cancer biology continue to evolve. At the same time, it is essential to invest in ongoing research so that it helps not only identify newer mutations but also develop drugs that can target them and control cancer growth. However, it is essential to understand that treatment with targeted drugs can result in the tumor acquiring newer mutations, leading to drug resistance, which is why repeated biopsies and testing as disease advances may become critical and necessary.”